Results 91 to 100 of about 5,892 (166)

Duloxetine-Induced Antidiuresis in Rats with Lithium-Induced Nephrogenic Diabetes Insipidus

Life
Antidepressants, including duloxetine, are a significant cause of drug-induced hyponatremia, which can disrupt the continuation of medication. Tolvaptan is beneficial for correcting hyponatremia caused by the syndrome of inappropriate antidiuresis, but ...
Sua Kim, Chor Ho Jo, Gheun-Ho Kim
doaj   +1 more source

Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT‐1 and SALT‐2 trials

Cancer Medicine, 2017
Hyponatremia is a common electrolyte disorder in cancer patients and has been associated with poor prognosis. A frequent cause of cancer‐related hyponatremia is the syndrome of inappropriate antidiuretic hormone (SIADH).
Richard J. Gralla, Fatima Ahmad, Jaime D. Blais, Joseph Chiodo III, Wen Zhou, Linda A. Glaser, Frank S. Czerwiec   +6 more
doaj   +1 more source

Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes

, 2020
Tolvaptan is a selective V 2 -receptor antagonist primarily metabolized by CYP 3A. The present study investigated the hepatocellular disposition of tolvaptan and the generated tolvaptan metabolites, DM-4103 and DM-4107, as well as the potential for drug ...
Lu
core  

Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD

Kidney International Reports
Introduction: Tolvaptan has been shown to reduce renal volume and delay disease progression in autosomal-dominant polycystic kidney disease (ADPKD). However, no biomarkers are currently available to guide dose adjustment.
F.J. Roca Oporto, C. Andrades Gómez, G. Montilla Cosano, A. Luna Aguilera, José L. Rocha   +4 more
doaj   +1 more source

The impact of tolvaptan on autosomal dominant polycystic kidney disease – literature review

Studia Medyczne
This article presents current data from international literature on the impact of tolvaptan on autosomal dominant polycystic kidney disease (ADPKD). The authors have reviewed the latest clinical research literature.
Anna Gruszczyńska, Krzysztof Kowalik, Grażyna Dutkiewicz, Anna Rakoczy, Andrzej Modrzejewski   +4 more
doaj   +1 more source

[From hyponatremia to tolvaptan]

, 2014
Hyponatremia is the electrolytic disorder that is observed most frequently in hospitalized patients. Itinfluences prognosis in the short, mid and long term.
MONTALTO, Gaetano, CERNARO, VALERIA, LACQUANITI, ANTONIO, SANTORO, Domenico, BUEMI, Michele   +4 more
core  

Tolvaptan slows disease progression in late-stage ADPKD

, 2018
New data from the REPRISE trial confirms that tolvaptan slows the progression of autosomal dominant polycystic disease (ADPKD). Although not yet approved by the United States Food and Drug administration, tolvaptan is now likely to become standard care ...
Ong, A.C.M.
core   +1 more source

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease Revisited

, 2018
In the past, Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease (ADPKD) andits Outcomes (TEMPO) trial showed Tolvaptan, a vasopressin V2-receptor antagonist, slowed the decline in the estimatedGlomerular ...
Soroush Nomigolzar, BSc, RPSGT, MS, Himax Patel, BSc, MS   +1 more
core  

The long-term effect of tolvaptan treatment on kidney function and volume in patients with ADPKD [PDF]

BACKGROUND AND HYPOTHESIS: The only therapy to ameliorate disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD) is tolvaptan, a vasopressin V2 receptor antagonist.
Bais, Thomas, Bais, Thomas; id_orcid, Knol, Martine G E, Meijer, Esther, Kuiken, Vera, Gansevoort, Ron T, Geertsema, Paul, Casteleijn, Niek F, Vart, Priya   +8 more
core   +1 more source

Association Between Tolvaptan Exposure and Venous Thromboembolism Risk in ADPKD: A Real-World Propensity-Matched EHR Study. [PDF]

Nephrology (Carlton)
Chen TP, Tsai SF.
europepmc   +1 more source